2-[2,6-dibromo-4-(9-bromo-3-methyl-2-morpholin-4-ylmethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-3-phenyl-propionic acid | 477528-55-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[2,6-dibromo-4-(9-bromo-3-methyl-2-morpholin-4-ylmethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-3-phenyl-propionic acid
• 英文别名: 2-[2,6-Dibromo-4-[9-bromo-3-methyl-2-(morpholin-4-ylmethyl)benzo[f][1]benzothiol-4-yl]phenoxy]-3-phenylpropanoic acid
• CAS: 477528-55-5
• 化学式: C₃₃H₂₈Br₃NO₄S
• 分子量: 774.368
• InChiKey: UOTUFQTUQYABEE-UHFFFAOYSA-N

物化性质

• 沸点：
  788.6±60.0 °C(Predicted)
• 密度：
  1.656±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  42
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  87.2
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• PTPase inhibitors for improving cardiovascular risk profile
  申请人：Wyeth

  公开号：US20030022896A1

  公开（公告）日：2003-01-30

  This invention provides methods of using Protein-tyrosine phosphatase (PTPase) inhibitors for lowering the cardiovascular risk profile in mammals experiencing or subject to type II diabetes or Syndrome X, including lowering levels of blood lipoproteins, free fatty acids and triglycerides, as well as treating, preventing or inhibiting atherosclerosis and other cardiovascular and cerebebrovascular disorders.

  本发明提供了使用蛋白酪氨酸磷酸酶（PTPase）抑制剂降低患有或受到2型糖尿病或X综合征影响的哺乳动物心血管风险状况的方法，包括降低血脂蛋白、游离脂肪酸和三酰甘油水平，以及治疗、预防或抑制动脉粥样硬化和其他心血管和脑血管疾病。
• Combination of a PTPase inhibitor and a thiazolidinedione agent
  申请人：Wyeth

  公开号：US20020198203A1

  公开（公告）日：2002-12-26

  This invention provides methods of using a pharmacological combination of one or more PTPase inhibiting agents and one or more thiazolidinedione agents, including pioglitizone or rosiglitazone, for treatment in a mammal of Syndrome X or type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose levels in a mammal utilizing the combination of one or more PTPase inhibiting agents and one or more thiazolidinedione agents.

  这项发明提供了一种使用一种或多种PTP酶抑制剂和一种或多种噻唑烷二酮类药物的药物组合的方法，包括吡格列酮或罗格列酮，用于治疗哺乳动物的X综合症，2型糖尿病或由胰岛素抵抗或高血糖介导的代谢紊乱。此外，本发明还包括一种利用一种或多种PTP酶抑制剂和一种或多种噻唑烷二酮类药物的组合调节哺乳动物血糖水平的方法。
• Combination of a PTPase inhibitor and a sulfonylurea agent
  申请人：Wyeth

  公开号：US20030008869A1

  公开（公告）日：2003-01-09

  This invention provides pharmaceutical compositions and methods of treatment and control of Syndrome X or type II diabetes in a mammal utilizing a combination of a sulfonylurea agent and a protein-tyrosine phosphatase (PTPase) inhibitors.

  本发明提供了一种利用磺酰脲类药物和蛋白酪氨酸磷酸酶（PTPase）抑制剂的组合物，用于治疗和控制哺乳动物的X综合征或2型糖尿病的药物组合和治疗方法。
• Combination therapy for type II diabetes or Syndrome X
  申请人：Wyeth

  公开号：US20030018028A1

  公开（公告）日：2003-01-23

  This invention provides methods of using a pharmacological combination of a biguanide agents, such as metformin, and one or more PTPase inhibiting agents and, optionally, one or more sulfonlylurea agents, including glyburide, glyburide, glipizide, glimepiride, chlorpropamide, tolbutamide, or tolazamide, for treatment in a mammal of Syndrome X, type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose levels in a mammal utilizing the combination of one or more PTPase inhibiting agents and one or more sulfonlylurea agents.

  本发明提供了使用一种双胍类药物如二甲双胍和一种或多种PTPase抑制剂，以及可选的一种或多种磺酰脲类药物，包括格列吡嗪、格列本脲、格列齐特、格列美脲、氯丙苯胺、甲磺丁脲或甲酰胺噻唑，用于治疗哺乳动物的X综合症、2型糖尿病或由胰岛素抵抗或高血糖介导的代谢障碍的方法。本发明还包括使用一种或多种PTPase抑制剂和一种或多种磺酰脲类药物的组合来调节哺乳动物的血糖水平的方法。
• Methods using PTPase inhibitors and insulin
  申请人：Wyeth

  公开号：US20020187980A1

  公开（公告）日：2002-12-12

  This invention provides methods for utilizing a PTPase inhibiting compounds and one or more insulins in methods for use in control and maintenance of type II diabetes in a mammal, for improving the cardiovascular and cerebrovascular risk profiles, reduction of hyperlipidemia, lowering low density lipoprotein blood levels, lowering free fatty acid blood levels and triglyceride levels and inhibition, prevention or reduction of atherosclerosis in a type II diabetic, or the risk factors thereof.

  本发明提供了一种利用PTPase抑制化合物和一种或多种胰岛素的方法，用于控制和维持哺乳动物II型糖尿病，改善心血管和脑血管风险状况，降低高脂血症，降低低密度脂蛋白血液水平，降低游离脂肪酸血液水平和甘油三酯水平，并抑制、预防或减少II型糖尿病或其风险因素的动脉粥样硬化的方法。